ARN-3236 is primarily investigated for its potential therapeutic applications in the treatment of various cancers. It functions as a selective inhibitor of SIK2 (salt-inducible kinase 2), which plays a role in cancer cell survival and proliferation. By targeting SIK2, ARN-3236 aims to disrupt signaling pathways that promote tumor growth, making it a promising candidate for ovarian cancer and other malignancies. Its application is currently focused on preclinical and clinical studies to evaluate its efficacy, safety, and potential as part of combination therapies. Researchers are also exploring its role in overcoming drug resistance in certain cancers, offering a new avenue for targeted cancer treatment strategies.